D-dimer levels and COVID-19 severity: Systematic Review and Meta-Analysis.

D-dimer seviyeleri ve COVID-19 şiddeti: Sistematik Derleme ve Meta-analiz.

Journal

Tuberkuloz ve toraks
ISSN: 0494-1373
Titre abrégé: Tuberk Toraks
Pays: Turkey
ID NLM: 0417364

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 15 1 2021
pubmed: 16 1 2021
medline: 23 1 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is a fatal and pandemic disease discovered in December 2019 in Wuhan, with lots of asymptomatic cases and a long incubation period. The researchers suggested that high d-dimer levels could predict disease severity, lung complications, and thromboembolic events before they occur. We searched in PubMed, Scopus, and Web of Science using the keywords "D-dimer" and "coronavirus" or "D-dimer" and "COVID-19." We used Standardized Mean Differences (SMD) to build forest plots of continuous data and assess differences in serum D-dimer concentrations between severe and non-severe patients with COVID-19 disease. We evaluated p-value < 0.05 as statistically significant and preferred 95% confidence intervals (CIs). The pooled results of all studies revealed that the D-dimer concentrations were significantly higher in patients with more severe COVID-19 (SMD: 2.32 μg/mL; 95% CI, 0.72 3.92 μg/mL, p< 0.001). We evaluated severe patients with total D-dimer levels. D-dimer concentrations were significantly higher in severe patients against total COVID-19 patients (SMD: 2.01 μg/mL; 95% CI, 0.25 to 3.77 μg/mL, p= 0.08). We do not know the D-dimer increment mechanism in severe patients yet, but we think that these findings will be useful in the early diagnosis of severe disease and the first treatment.

Identifiants

pubmed: 33448732
doi: 10.5578/tt.70351
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-360

Auteurs

Muhammed Emin Düz (ME)

Department of Medical Biochemistry, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, Turkey.

Aydın Balcı (A)

Department of Chest Diseases, Afyonkarahisar University Faculty of Medicine, Afyonkarahisar, Turkey.

Elif Menekşe (E)

Department of Medical Biochemistry, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH